GERN [NASD]
Geron Corporation
Index- P/E- EPS (ttm)-0.34 Insider Own0.10% Shs Outstand403.87M Perf Week-14.81%
Market Cap929.41M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float361.92M Perf Month-2.13%
Income-116.90M PEG- EPS next Q-0.10 Inst Own52.30% Short Float4.31% Perf Quarter67.88%
Sales1.30M P/S714.93 EPS this Y-27.20% Inst Trans5.67% Short Ratio3.97 Perf Half Y85.48%
Book/sh0.35 P/B6.57 EPS next Y-18.40% ROA-52.50% Target Price4.20 Perf Year58.62%
Cash/sh0.54 P/C4.24 EPS next 5Y5.00% ROE-90.40% 52W Range0.99 - 3.06 Perf YTD88.52%
Dividend- P/FCF- EPS past 5Y-13.80% ROI-64.70% 52W High-25.16% Beta0.80
Dividend %- Quick Ratio4.90 Sales past 5Y-25.70% Gross Margin- 52W Low131.34% ATR0.18
Employees69 Current Ratio4.90 Sales Q/Q0.00% Oper. Margin- RSI (14)41.55 Volatility7.21% 7.16%
OptionableYes Debt/Eq0.36 EPS Q/Q23.00% Profit Margin- Rel Volume0.60 Prev Close2.30
ShortableYes LT Debt/Eq0.32 EarningsAug 11 AMC Payout- Avg Volume3.93M Price2.29
Recom1.60 SMA20-12.63% SMA50-0.53% SMA20047.38% Volume1,790,776 Change-0.43%
Jul-28-22Resumed B. Riley Securities Buy $4
Nov-02-21Initiated Robert W. Baird Outperform $4
Feb-18-21Resumed B. Riley Securities Buy $4
Aug-03-20Initiated Stifel Buy $3
Nov-19-19Resumed B. Riley FBR Buy $4
Sep-03-19Initiated H.C. Wainwright Buy $4
Aug-15-19Initiated Cantor Fitzgerald Overweight $4
Apr-09-19Upgrade Needham Hold → Buy $3
Jan-31-19Upgrade B. Riley FBR Neutral → Buy $1.50 → $3.25
Oct-02-18Downgrade B. Riley FBR Buy → Neutral $5.75 → $1.50
Jul-05-18Initiated B. Riley FBR, Inc. Buy $5.75
Sep-13-16Reiterated FBR Capital Outperform $6 → $5
Sep-13-16Reiterated FBR & Co. Outperform $6 → $5
Dec-07-15Reiterated Piper Jaffray Overweight $5 → $10
Apr-21-15Initiated Oppenheimer Outperform $5.50
Jun-12-14Upgrade MLV & Co Hold → Buy $2 → $4.25
Mar-12-14Downgrade MLV & Co Buy → Hold $9 → $2
Dec-10-13Upgrade Needham Hold → Buy $10
Dec-10-13Reiterated MLV & Co Buy $8 → $9
Nov-08-13Reiterated MLV & Co Buy $6.50 → $8
Sep-22-22 04:30PM
Sep-14-22 06:43AM
Sep-08-22 04:15PM
Sep-01-22 04:30PM
Aug-31-22 04:55PM
04:33PM
Aug-22-22 04:15PM
09:11AM
Aug-18-22 04:30PM
Aug-12-22 11:21AM
Aug-11-22 11:00PM
05:24PM
04:05PM
Aug-10-22 02:54PM
Aug-09-22 12:14PM
12:03PM
Aug-04-22 04:30PM
12:00PM
Aug-03-22 04:30PM
Jul-21-22 07:05PM
Jul-13-22 10:18AM
Jul-08-22 11:44AM
Jul-07-22 11:30AM
Jul-01-22 11:01AM
Jun-30-22 04:15PM
Jun-29-22 10:28AM
Jun-28-22 08:49AM
Jun-27-22 01:21PM
01:06PM
Jun-24-22 12:30PM
Jun-17-22 11:31AM
09:36AM
Jun-16-22 04:30PM
12:15PM
Jun-15-22 04:10PM
Jun-13-22 06:13AM
Jun-10-22 11:57AM
09:40AM
Jun-08-22 11:45AM
May-31-22 09:21AM
May-30-22 03:10PM
03:03PM
May-23-22 12:26PM
11:46AM
May-19-22 04:30PM
12:15PM
May-17-22 04:30PM
11:33AM
11:30AM
May-10-22 12:21PM
02:09AM
May-09-22 05:55PM
04:05PM
May-02-22 04:30PM
May-01-22 08:39AM
Apr-21-22 04:30PM
Apr-07-22 05:51AM
Apr-06-22 04:30PM
Apr-01-22 04:15PM
Mar-30-22 05:24PM
02:25AM
Mar-29-22 04:01PM
Mar-17-22 04:30PM
Mar-10-22 09:00PM
04:06PM
Mar-03-22 04:30PM
Jan-31-22 10:18AM
Jan-26-22 10:05AM
Jan-21-22 07:30AM
Jan-20-22 04:30PM
Jan-04-22 05:01PM
Dec-16-21 04:30PM
Dec-14-21 04:30PM
Dec-02-21 07:30AM
Nov-18-21 04:30PM
Nov-12-21 07:30AM
Nov-09-21 09:05PM
06:00PM
Nov-04-21 09:12AM
Oct-31-21 10:44AM
Oct-28-21 03:06PM
Oct-25-21 04:30PM
Oct-21-21 04:30PM
Oct-18-21 07:30AM
Oct-15-21 04:05PM
Oct-11-21 04:30PM
Sep-16-21 04:30PM
Sep-01-21 04:30PM
Aug-28-21 08:01AM
Aug-19-21 04:30PM
Aug-17-21 08:28AM
05:00AM
Aug-16-21 05:25PM
04:06PM
Aug-05-21 04:30PM
Aug-02-21 06:09AM
Jul-29-21 03:05PM
Jul-22-21 04:45PM
Jun-21-21 12:15PM
08:36AM
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRETHLEIN ANDREW JEVP, Chief Operating OfficerSep 12Option Exercise1.70234,719399,022234,719Sep 14 05:47 PM
EASTHAM KARINDirectorApr 20Option Exercise1.4135,00049,35074,047Apr 21 08:09 PM